Showing 7981-7990 of 18164 results for "".
Emerging Tickborne Diseases
https://reachmd.com/programs/grand-rounds-nation/emerging-tickborne-diseases/9449/CDC experts discuss emerging tickborne diseases, treatment options, prevention strategies, and diagnostic advances.Are Pregnant Women Who Have Had Bariatric Surgery at a Higher Risk for Birth Complications?
https://reachmd.com/programs/the-jama-report/are-pregnant-women-who-have-had-bariatric-surgery-higher-risk-birth-complications/8395/New research in JAMA found that women who had undergone bariatric surgery and gave birth within 2-3 years had a higher risk of complications.The Politics of Measles: Ethical Considerations in the National Vaccination Debate
https://reachmd.com/programs/primary-care-today/politics-measles-ethical-considerations-national-vaccination-debate/7297/The controversy over vaccinations and whether or not to regulate their administration has reached a boiling point in the United States with the recent measles outbreak originating in Disneyland, and prominent politicians like Senator Rand Paul and Governor Chris Christie have weighed in to support tFive Days at Memorial: Life and Death in a Storm-Ravaged Hospital, Part 1
https://reachmd.com/programs/book-club/five-days-at-memorial-life-and-death-in-a-storm-ravaged-hospital-part-1/6929/In her book, Five Days at Memorial, physician and reporter Sheri Fink reconstructs 5 days at Memorial Medical Center and draws the reader into the lives of those who struggled mightily to survive and to maintain life amid chaos. Drawing from a culmination of six years of reporting, Dr. Fink unspoolsVoices of Experience: How To Speak About Medicine
https://reachmd.com/programs/primary-care-today/voices-of-experience-how-to-speak-about-medicine/6789/Joining Dr. Brian McDonough is Dr. Tom Linden, the Glaxo Wellcome Distinguished Professor of Medical Journalism at the University of North Carolina. Dr. Linden directs the Medical & Science Journalism Program, one of the nation's first master's programs in medical journalism. He is also the authThe Complexity of Medication Management for Older Patients with Heart Failure
https://reachmd.com/programs/heart-matters/the-complexity-of-medication-management-for-older-patients-with-heart-failure/6251/One of the characteristics of our older patients with heart failure is that they often have other conditions and therefore take multiple medications. How can we reduce the risk of adverse drug events among patients with heart failure and other comorbidities? Dr. Michael Steinman, associate professorThe Scientific Pursuit of More Precise Care
https://reachmd.com/programs/heart-matters/the-scientific-pursuit-of-more-precise-care/4790/Patient-centered care is a hot topic in health care these days, though usually when we think of patient-centeredness, our thinking tilts toward aspects of policymaking or system delivery. Host Dr. Janet Wright takes a look at the science side of patient-centered care — the more precise tailoring ofBoarded in the ED: A Look at Mortality and Morbidity
https://reachmd.com/programs/clinicians-roundtable/boarded-in-the-ed-a-look-at-mortality-and-morbidity/4568/Patients that come into an emergency room sometimes have to wait hours even days before they are moved to a hospital floor. A new study says more than a quarter of patients who are "boarded" in the ER after being admitted to the hospital often suffer undesirable events like missing necessary treatmeIs the PA Profession Recession-Proof?
https://reachmd.com/programs/clinicians-roundtable/is-the-pa-profession-recession-proof/4409/Despite the current economic recession in the United States, the PA profession is growing at a rapid pace. Currently there are 73,000 PAs nationwide and 5000 new PAs are graduating every year. Cynthia Lord, president of the American Academy of Physician Assistants and the program director of the PhyBeyond the Embryonic Stem Cell Debate
https://reachmd.com/programs/clinicians-roundtable/beyond-the-embryonic-stem-cell-debate/4314/Although President Obama has favored funding for embryonic stem cell research, the moral debate continues. But that discussion may overshadow the fact that biotech companies have actually made the most early progress, not in embryonic stem cells, but in adult stem cells. Dr. Robert Harman, chief exe